Prospects for a MERS-CoV spike vaccine
Top Cited Papers
- 3 August 2018
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Vaccines
- Vol. 17 (8), 677-686
- https://doi.org/10.1080/14760584.2018.1506702
Abstract
Introduction: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines. Areas covered: In this review, we illustrate the structure and function of S protein as a vaccine target, describe available animal models for evaluating MERS vaccines, and summarize recent progress on MERS-CoV S-based vaccines, focusing on their ability to elicit antibody and/or cellular immune responses, neutralizing antibodies, and protection against MERS-CoV infection in different models. Prospects for future MERS-CoV S-based vaccines are discussed. Expert commentary: The majority of MERS vaccines under development are based on MERS-CoV S protein, including full-length S, S1, and receptor-binding domain (RBD). While it is essential to evaluate the safety of full-length S and S1-based MERS vaccines, further improvement of the efficacy of RBD-based vaccines using novel strategies would be necessary. Overall, this review provides informative guidance for designing and developing safe and effective MERS vaccines based on viral S protein.Keywords
Funding Information
- NIH (R01AI137472, R01AI139092, R21AI128311)
This publication has 92 references indexed in Scilit:
- Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing AntibodiesJournal of Virology, 2013
- Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome CoronavirusJournal of Virology, 2013
- Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine DevelopmentJournal of Virology, 2013
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?The Journal of Experimental Medicine, 2008
- Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferretsVaccine, 2005
- Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in FerretsJournal of Virology, 2004